Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial
Matthew R. Weir(University of Maryland, Baltimore), Thomas C. Pearson(Emory Healthcare), Roberto N. Kalil(University of Iowa Hospitals and Clinics), Thomas Waid(University of Kentucky), Shamkant Mulgaonkar(Saint Barnabas Medical Center), Dennis Preston(Genentech), Laurence Chan(University of Oxford), Hamid Shidban(Mendez National Institute of Transplantation)
Cited by 183
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
|New England Journal of Medicine|2014|658
MYH9 is associated with nondiabetic end-stage renal disease in African Americans
|Nature Genetics|2008|648